304 related articles for article (PubMed ID: 31139950)
1. Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome.
Olsson P; Bodewes ILA; Nilsson AM; Turesson C; Jacobsson LTH; Theander E; Versnel MA; Mandl T
Rheumatol Int; 2019 Sep; 39(9):1575-1584. PubMed ID: 31139950
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
3. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
4. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.
Cho HJ; Yoo JJ; Yun CY; Kang EH; Lee HJ; Hyon JY; Song YW; Lee YJ
Rheumatology (Oxford); 2013 Dec; 52(12):2208-17. PubMed ID: 24023247
[TBL] [Abstract][Full Text] [Related]
5. Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome?
Manthorpe R; Benoni C; Jacobsson L; Kirtava Z; Larsson A; Liedholm R; Nyhagen C; Tabery H; Theander E
Ann Rheum Dis; 2000 Jan; 59(1):54-60. PubMed ID: 10627428
[TBL] [Abstract][Full Text] [Related]
6. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
[TBL] [Abstract][Full Text] [Related]
7. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
8. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
[TBL] [Abstract][Full Text] [Related]
9. Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity.
Bodewes ILA; Al-Ali S; van Helden-Meeuwsen CG; Maria NI; Tarn J; Lendrem DW; Schreurs MWJ; Steenwijk EC; van Daele PLA; Both T; Bowman SJ; Griffiths B; Ng WF; ; Versnel MA
Rheumatology (Oxford); 2018 May; 57(5):921-930. PubMed ID: 29474655
[TBL] [Abstract][Full Text] [Related]
10. Impact of sleep quality on clinical features of primary Sjögren's syndrome.
Chung SW; Hur J; Ha YJ; Kang EH; Hyon JY; Lee HJ; Song YW; Lee YJ
Korean J Intern Med; 2019 Sep; 34(5):1154-1164. PubMed ID: 29458245
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
12. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
[TBL] [Abstract][Full Text] [Related]
13. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?
Lendrem D; Mitchell S; McMeekin P; Gompels L; Hackett K; Bowman S; Price E; Pease CT; Emery P; Andrews J; Lanyon P; Hunter J; Gupta M; Bombardieri M; Sutcliffe N; Pitzalis C; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Griffiths B; Ng WF;
Rheumatology (Oxford); 2015 Apr; 54(4):655-9. PubMed ID: 25240612
[TBL] [Abstract][Full Text] [Related]
14. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P
Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
[TBL] [Abstract][Full Text] [Related]
15. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z
Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244
[TBL] [Abstract][Full Text] [Related]
16. Cigarette smoking in primary Sjögren's syndrome: positive association only with ANA positivity.
Karabulut G; Kitapcioglu G; Inal V; Kalfa M; Yargucu F; Keser G; Emmungil H; Gokmen NM; Kocanaogullari H; Aksu K
Mod Rheumatol; 2011 Dec; 21(6):602-7. PubMed ID: 21445716
[TBL] [Abstract][Full Text] [Related]
17. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
[TBL] [Abstract][Full Text] [Related]
19. Smoking, disease characteristics and serum cytokine levels in patients with primary Sjögren's syndrome.
Olsson P; Skogstrand K; Nilsson A; Turesson C; Jacobsson LTH; Theander E; Houen G; Mandl T
Rheumatol Int; 2018 Aug; 38(8):1503-1510. PubMed ID: 29846789
[TBL] [Abstract][Full Text] [Related]
20. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
